Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Argenx SE
  6. Summary
    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
Real-time Euronext Bruxelles  -  10:12:31 2023-02-02 am EST
343.60 EUR   -0.38%
01/27Sector Update: Health Care Stocks' Recovery Stall Short of Positive Ground
MT
01/27Sector Update: Health Care Stocks Sinking as Investor Attention Looks to Other Sectors
MT
01/27European Equities Move Lower Friday, Set to End Week in Negative Territory
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
01/27/2023 01/30/2023 01/31/2023 02/01/2023 02/02/2023 Date
346.6(c) 346.6(c) 347(c) 344.9(c) 343.6 Last
76 573 46 642 56 184 42 590 18 536 Volume
-1.20% 0.00% +0.12% -0.61% -0.38% Change
More quotes
Estimated financial data (e)
Sales 2022 415 M 453 M 453 M
Net income 2022 -790 M -862 M -862 M
Net cash position 2022 1 640 M 1 791 M 1 791 M
P/E ratio 2022 -24,8x
Yield 2022 -
Sales 2023 832 M 908 M 908 M
Net income 2023 -519 M -566 M -566 M
Net cash position 2023 1 438 M 1 570 M 1 570 M
P/E ratio 2023 -38,2x
Yield 2023 -
Capitalization 19 124 M 20 880 M 20 880 M
EV / Sales 2022 42,2x
EV / Sales 2023 21,3x
Nbr of Employees 650
Free-Float 100%
More Financials
Company
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune... 
Sector
Biotechnology & Medical Research
Calendar
02/27 | 06:00amShareholder meeting
More about the company
Ratings of argenx SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ARGENX SE
01/27Sector Update: Health Care Stocks' Recovery Stall Short of Positive Ground
MT
01/27Sector Update: Health Care Stocks Sinking as Investor Attention Looks to O..
MT
01/27European Equities Move Lower Friday, Set to End Week in Negative Territory
MT
01/27Sector Update: Health Care Stocks Flat to Lower Premarket Friday
MT
01/27Argenx Says US FDA Lenghtens Review for Investigational Treatment of Generalized Myasth..
MT
01/27US FDA Extends Review Of Argenx's Myasthenia Gravis Treatment
MT
01/27argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
GL
01/27Argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
AQ
01/27Argenx SE Receives Notification of PDUFA Date Extension for SC Efgartigimod
CI
01/25Cowen Adjusts Price Target on argenx to $458 From $441, Maintains Outperform Rating
MT
01/18Argenx : BlackRock Inc. - argenx SE - Breda
PU
01/16argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to ..
GL
01/16Argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to ..
AQ
01/16Argenx SE Announces Werner Lanthaler Will Resign as Non-Executive Director of Board and..
CI
01/11Argenx : BlackRock Inc. - argenx SE - Breda
PU
More news
News in other languages on ARGENX SE
05:47aHalf procent winst in Brussel
01/30Zwaargewichten houden verlies Bel20 beperkt
01/29Week: nauwelijks beweging in Bel20
01/27Mise à jour sectorielle : La reprise des actions du secteur de l..
01/27Mise à jour sectorielle : Les actions du secteur de la santé som..
More news
Analyst Recommendations on ARGENX SE
More recommendations
ETFs positioned on ARGENX SEETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Lyxor BEL 20 TR (DR) - Dist - EUR12.05%0.11%Belgium
IShares MSCI EMU Mid Cap - EUR2.92%0.38%Europe
UBS ETF ? MSCI EMU Socially Responsible A-...2.08%1.30%-NC
UBS ETF ? MSCI EMU Socially Responsible A-...2.08%1.05%-NC
UBS ETF (LU) MSCI EMU Socially Responsible ...2.08%0.64%-NC
More ETFs positioned on ARGENX SE
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 344,90 €
Average target price 463,59 €
Spread / Average Target 34,4%
EPS Revisions
Managers and Directors
Tim van Hauwermeiren Chief Executive Officer
Karl Gubitz Chief Financial Officer
Peter K. M. Verhaeghe Non-Executive Chairman
Hans J. W. de Haard Chief Scientific Officer
Luc Truyen Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ARGENX SE-0.98%20 880
VERTEX PHARMACEUTICALS11.88%81 440
REGENERON PHARMACEUTICALS, INC.5.06%80 956
WUXI APPTEC CO., LTD.15.90%40 901
BIONTECH SE-4.77%34 764
BEIGENE, LTD.15.61%26 436